中国药房2017，Vol.28Issue(9)：1211-1215,5.DOI:10.6039/j.issn.1001-0408.2017.09.17
西地那非治疗新生儿持续性肺动脉高压的系统评价
Sildenafil in the Treatment of Peristent Pulmonary Hypertension in Newborns:A Systematic Review
摘要
Abstract
OBJECTIVE:To systematically review the clinical efficacy of sildenafil in the treatment of persistent pulmonary hy-pertension in newborns(PPHN),and to provide evidence-based reference in the clinic. METHODS:Retrieved from PubMed,Co-chrane Library,EMBase(Ovid),CBM,CJFD,Wanfang and VIP,randomized controlled trials(RCTs)about sildenafil(test group) versus basic therapy or placebo in the treatment of PPHN were collected. Meta-analysis was performed by using Rev Man 5.1 soft-ware after data extraction and quality evaluation by Cochrane 5.1.0. RESULTS:Totally 6 RCTs were enrolled,involving 210 pa-tients. Results of Meta-analysis showed,compared with placebo,sildenafil can significantly reduce the mortality [RR=0.16,95%CI (0.05,0.45),P<0.001] and the oxygenation index [after 2 h:MD=-12.80,95%CI(-20.11,-5.49),P<0.001;after 24 h:MD=-19.41,95%CI(-24.81,-14.00),P<0.001],with statistical significances;compared with basic therapy,sildenafil can signifi-cantly reduce pulmonary arterial pressure [after 2 h:MD=-22.36,95%CI(-24.89,-19.83),P<0.001;after 24 h:MD=-29.43, 95%CI(-31.12,-27.74),P<0.001],with statistical significances,but there was no statistical difference in mortality[RR=0.64, 95%CI(0.30,1.39),P=0.26]. CONCLUSIONS:Sildenafil is effective in the treatment of PPHN,it can significantly reduce the ox-ygenation index,pulmonary arterial pressure and mortality.关键词
西地那非/持续性肺动脉高压/Meta分析/新生儿/疗效Key words
Sildenafil/Persistent pulmonary hypertension/Meta-analysis/Newborn/Efficacy分类
医药卫生引用本文复制引用
蒋璐灿,全淑燕,李佳莲,归舸,石晶,张伶俐..西地那非治疗新生儿持续性肺动脉高压的系统评价[J].中国药房,2017,28(9):1211-1215,5.基金项目
国家自然科学基金资助项目(No.81373381) （No.81373381）
